Does Elidel (pimecrolimus) cause side effects?
Elidel (pimecrolimus) is an immunosuppressant used to treat atopic dermatitis (eczema), a skin condition characterized by
- redness,
- itching,
- scaling, and
- inflammation of the skin.
Scientists believe atopic dermatitis may be due to activation of the immune system by various environmental or emotional triggers.
It is not known exactly how Elidel reduces the manifestations of atopic dermatitis, but Elidel reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system.
Elidel prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Elidel also reduces the ability of mast cells to release chemicals that promote inflammation.
Common side effects of Elidel include
- application site reactions (burning, itching, and redness),
- sore throat,
- stuffy nose,
- headache,
- cough,
- respiratory tract and viral infections.
Serious side effects of Elidel include
- skin cancer and
- lymphoma (rare).
Drug interactions of Elidel and other drugs have not been studied. Since very little Elidel is absorbed from the skin, drug interactions are not expected.
Since some Elidel is absorbed, caution should be exercised when Elidel is used by individuals also taking drugs that inhibit the liver enzymes that eliminate Elidel and could increase the levels of Elidel and promote its toxicity such as
There are no adequate studies that evaluate the use of Elidel during pregnancy. Use of Elidel by nursing mothers has not been evaluated, and it is unknown if Elidel is excreted in breast milk. Breastfeeding mothers should decide whether to stop nursing or use alternative treatments.
What are the important side effects of Elidel (pimecrolimus)?
The most common side effects of pimecrolimus are:
- reactions at the site of application,
- burning,
- itching, and
- redness.
Other important side effects include:
- sore throat,
- stuffy nose,
- headache,
- cough,
- respiratory tract and
- viral infections.
Skin cancer and lymphoma have rarely occurred during treatment with pimecrolimus. Therefore, pimecrolimus should not be used for long-term treatment and should only be applied to affected areas.
Elidel (pimecrolimus) side effects list for healthcare professionals
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
No phototoxicity and no photoallergenicity were detected in clinical trials with 24 and 33 normal volunteers, respectively. In human dermal safety trials, Elidel (pimecrolimus) Cream, 1% did not induce contact sensitization or cumulative irritation.
In a one-year safety trial in pediatric subjects age 2-17 years old involving sequential use of Elidel Cream, 1% and a topical corticosteroid, 43% of Elidel Cream, 1% treated subjects and 68% of vehicle -treated subjects used corticosteroids during the trial.
- Corticosteroids were used for more than 7 days by 34% of Elidel Cream, 1% treated subjects and 54% of vehicle -treated subjects.
- An increased incidence of impetigo, skin infection, superinfection (infected atopic dermatitis), rhinitis, and urticaria were found in the subjects that had used Elidel Cream, 1% and topical corticosteroid sequentially as compared to Elidel Cream, 1% alone.
In 3 randomized, double-blind vehicle-controlled pediatric trials and one active-controlled adult trial, 843 and 328 subjects respectively, were treated with Elidel Cream, 1%.
- In these clinical trials, 48 (4%) of the 1,171 Elidel treated subjects and 13 (3%) of 408 vehicle-treated subjects discontinued therapy due to adverse events.
- Discontinuations for AEs were primarily due to application site reactions, and cutaneous infections.
- The most common application site reaction was application site burning, which occurred in 8%-26% of subjects treated with Elidel Cream, 1%.
Table 1 depicts the incidence of adverse events pooled across the 2 identically designed 6-week trials with their open label extensions and the 1-year safety trial for pediatric subjects ages 2-17. Data from the adult active-controlled trial is also included in Table 1. Adverse events are listed regardless of relationship to trial drug.
Table 1: Treatment Emergent Adverse Events ( ≥ 1%) in Elidel® Treatment Groups
Pediatric Subjects* Vehicle-Controlled (6 weeks) | Pediatric Subjects* Open-Label (20 weeks) | Pediatric Subjects*Vehicle-Controlled (1 year) | Adult ActiveComparator (1 year) | |||
Elidel® Cream (N=267) N(%) | Vehicle (N=136) N (%) | Elidel® Cream (N=335) N (%) | Elidel® Cream (N=272) N(%) | Vehicle (N=75) N (%) | Elidel® Cream (N=328) N (%) | |
At least 1 AE | 182(68.20%) | 97(71.30%) | 240 (72.0%) | 230 (84.6%) | 56(74.70%) | 256 (78.0%) |
Infections and Infestations | ||||||
Upper Respiratory Tract Infection NOS | 38(14.2%) | 18(13.2%) | 65 (19.4%) | 13 (4.8%) | 6 (8.0%) | 14 (4.3%) |
Nasopharyngitis | 27(10.1%) | 10 (7.4%) | 32 (19.6%) | 72 (26.5%) | 16(21.3%) | 25 (7.6%) |
Skin Infection NOS | 8 (3.0%) | 9 (5.1%) | 18 (5.4%) | 6 (2.2%) | 3 (4.0%) | 21 (6.4%) |
Influenza | 8 (3.0%) | 1 (0.7%) | 22 (6.6%) | 36 (13.2%) | 3 (4.0%) | 32 (9.8%) |
Ear Infection NOS | 6 (2.2%) | 2 (1.5%) | 19 (5.7%) | 9 (3.3%) | 1 (1.3%) | 2 (0.6%) |
Otitis Media | 6 (2.2%) | 1 (0.7%) | 10 (3.0%) | 8 (2.9%) | 4 (5.3%) | 2 (0.6%) |
Impetigo | 5 (1.9%) | 3 (2.2%) | 12 (3.6%) | 11 (4.0%) | 4 (5.3%) | 8 (2.4%) |
Bacterial Infection | 4 (1.5%) | 3 (2.2%) | 4 (1.2%) | 3 (1.1%) | 0 | 6 (1.8%) |
Folliculitis | 3 (1.1%) | 1 (0.7%) | 3 (0.9%) | 6 (2.2%) | 3 (4.0%) | 20 (6.1%) |
Sinusitis | 3 (1.1%) | 1 (0.7%) | 11 (3.3%) | 6 (2.2%) | 1 (1.3%) | 2 (0.6%) |
Pneumonia NOS | 3 (1.1%) | 1 (0.7%) | 5 (1.5%) | 0 | 1 (1.3%) | 1 (0.3%) |
Pharyngitis NOS | 2 (0.7%) | 2 (1.5%) | 3 (0.9%) | 22 (8.1%) | 2 (2.7%) | 3 (0.9%) |
Pharyngitis Streptococcal | 2 (0.7%) | 2 (1.5%) | 10 (3.0%) | 0 | < 1% | 0 |
Molluscum Contagiosum | 2 (0.7%) | 0 | 4 (1.2%) | 5 (1.8%) | 0 | 0 |
Staphylococcal Infection | 1 (0.4%) | 5 (3.7%) | 7 (2.1%) | 0 | < 1% | 3 (0.9%) |
Bronchitis NOS | 1 (0.4%) | 3 (2.2%) | 4 (1.2%) | 29 (10.7%) | 6 (8.0%) | 8 (2.4%) |
Herpes Simplex | 1 (0.4%) | 0 | 4 (1.2%) | 9 (3.3%) | 2 (2.7%) | 13 (4.0%) |
Tonsillitis NOS | 1 (0.4%) | 0 | 3 (0.9%) | 17 (6.3%) | 0 | 2 (0.6%) |
Viral Infection NOS | 2 (0.7%) | 1 (0.7%) | 1 (0.3%) | 18 (6.6%) | 1 (1.3%) | 0 |
Gastroenteritis NOS | 0 | 3 (2.2%) | 2 (0.6%) | 20 (7.4%) | 2 (2.7%) | 6 (1.8%) |
Chickenpox | 2 (0.7%) | 0 | 3 (0.9%) | 8 (2.9%) | 3 (4.0%) | 1 (0.3%) |
Skin Papilloma | 1 (0.4%) | 0 | 2 (0.6%) | 9 (3.3%) | < 1% | 0 |
Tonsillitis Acute NOS | 0 | 0 | 0 | 7 (2.6%) | 0 | 0 |
Upper Respiratory Tract | ||||||
Infection Viral NOS | 1 (0.4%) | 0 | 3 (0.9%) | 4 (1.5%) | 0 | 1 (0.3%) |
Herpes Simplex Dermatitis | 0 | 0 | 1 (0.3%) | 4 (1.5%) | 0 | 2 (0.6%) |
Bronchitis Acute NOS | 0 | 0 | 0 | 4 (1.5%) | 0 | 0 |
Eye Infection NOS | 0 | 0 | 0 | 3 (1.1%) | < 1% | 1 (0.3%) |
General Disorders and Administration Site Conditions | ||||||
Application Site Burning | 28(10.4%) | 17(12.5%) | 5 (1.5%) | 23 (8.5%) | 5 (6.7%) | 85 (25.9%) |
Pyrexia | 20 (7.5%) | 12 (8.8%) | 41 (12.2%) | 34 (12.5%) | 4 (5.3%) | 4 (1.2%) |
Application Site Reaction | ||||||
NOS | 8 (3.0%) | 7 (5.1%) | 7 (2.1%) | 9 (3.3%) | 2 (2.7%) | 48 (14.6%) |
Application Site Irritation | 8 (3.0%) | 8 (5.9%) | 3 (0.9%) | 1 (0.4%) | 3 (4.0%) | 21 (6.4%) |
Influenza Like Illness | 1 (0.4%) | 0 | 2 (0.6%) | 5 (1.8%) | 2 (2.7%) | 6 (1.8%) |
Application Site Erythema | 1 (0.4%) | 0 | 0 | 6 (2.2%) | 0 | 7 (2.1%) |
Application Site Pruritus | 3 (1.1%) | 2 (1.5%) | 2 (0.6%) | 5 (1.8%) | 0 | 18 (5.5%) |
Respiratory, Thoracic and Mediastinal Disorders | ||||||
Cough | 31(11.6%) | 11 (8.1%) | 31 (9.3%) | 43 (15.8%) | 8 (10.7%) | 8 (2.4%) |
Nasal Congestion | 7 (2.6%) | 2 (1.5%) | 6 (1.8%) | 4 (1.5%) | 1 (1.3%) | 2 (0.6%) |
Rhinorrhea | 5 (1.9%) | 1 (0.7%) | 3 (0.9%) | 1 (0.4%) | 1 (1.3%) | 0 |
Asthma Aggravated | 4 (1.5%) | 3 (2.2%) | 13 (3.9%) | 3 (1.1%) | 1 (1.3%) | 0 |
Sinus Congestion | 3 (1.1%) | 1 (0.7%) | 2 (0.6%) | < 1% | < 1% | 3 (0.9%) |
Rhinitis | 1 (0.4%) | 0 | 5 (1.5%) | 12 (4.4%) | 5 (6.7%) | 7 (2.1%) |
Wheezing | 1 (0.4%) | 1 (0.7%) | 4 (1.2%) | 2 (0.7%) | < 1% | 0 |
Asthma NOS | 2 (0.7%) | 1 (0.7%) | 11 (3.3%) | 10 (3.7%) | 2 (2.7%) | 8 (2.4%) |
Epistaxis | 0 | 1 (0.7%) | 0 | 9 (3.3%) | 1 (1.3%) | 1 (0.3%) |
Dyspnea NOS | 0 | 0 | 0 | 5 (1.8%) | 1 (1.3%) | 2 (0.6%) |
Gastrointestinal Disorders | ||||||
Abdominal Pain Upper | 11 (4.1%) | 6 (4.4%) | 10 (3.0%) | 15 (5.5%) | 5 (6.7%) | 1 (0.3%) |
Sore Throat | 9 (3.4%) | 5 (3.7%) | 15 (5.4%) | 22 (8.1%) | 4 (5.3%) | 12 (3.7%) |
Vomiting NOS | 8 (3.0%) | 6 (4.4%) | 14 (4.2%) | 18 (6.6%) | 6 (8.0%) | 2 (0.6%) |
Diarrhea NOS | 3 (1.1%) | 1 (0.7%) | 2 (0.6%) | 21 (7.7%) | 4 (5.3%) | 7 (2.1%) |
Nausea | 1 (0.4%) | 3 (2.2%) | 4 (1.2%) | 11 (4.0%) | 5 (6.7%) | 6 (1.8%) |
Abdominal Pain NOS | 1 (0.4%) | 1 (0.7%) | 5 (1.5%) | 12 (4.4%) | 3 (4.0%) | 1 (0.3%) |
Toothache | 1 (0.4%) | 1 (0.7%) | 2 (0.6%) | 7 (2.6%) | 1 (1.3%) | 2 (0.6%) |
Constipation | 1 (0.4%) | 0 | 2 (0.6%) | 10 (3.7%) | < 1% | 0 |
Loose Stools | 0 | 1 (0.7%) | 4 (1.2%) | < 1% | < 1% | 0 |
Reproductive System and Breast Disorders | ||||||
Dysmenorrhea | 3 (1.1%) | 0 | 5 (1.5%) | 3 (1.1%) | 1 (1.3%) | 4 (1.2%) |
Eye Disorders | ||||||
Conjunctivitis NEC | 2 (0.7%) | 1 (0.7%) | 7 (2.1%) | 6 (2.2%) | 3 (4.0%) | 10 (3.0%) |
Skin & Subcutaneous Tissue Disorders | ||||||
Urticaria | 3 (1.1%) | 0 | 1 (0.3%) | 1 (0.4%) | < 1% | 3 (0.9%) |
Acne NOS | 0 | 1 (0.7%) | 1 (0.3%) | 4 (1.5%) | < 1% | 6 (1.8%) |
Immune System Disorders | ||||||
Hypersensitivity NOS | 11 (4.1%) | 6 (4.4%) | 16 (4.8%) | 14 (5.1%) | 1 (1.3%) | 11 (3.4%) |
Injury and Poisoning | ||||||
Accident NOS | 3 (1.1%) | 1 (0.7%) | 1 (0.3%) | < 1% | 1 (1.3%) | 0 |
Laceration | 2 (0.7%) | 1 (0.7%) | 5 (1.5%) | < 1% | < 1% | 0 |
Musculoskeletal, Connective Tissue and Bone Disorders | ||||||
Back Pain | 1 (0.4%) | 2 (1.5%) | 1 (0.3%) | < 1% | 0 | 6 (1.8%) |
Arthralgias | 0 | 0 | 1 (0.3%) | 3 (1.1%) | 1 (1.3%) | 5 (1.5%) |
Ear and Labyrinth Disorders | ||||||
Earache | 2 (0.7%) | 1 (0.7%) | 0 | 8 (2.9%) | 2 (2.7%) | 0 |
Nervous System Disorders | ||||||
Headache | 37(13.9%) | 12 (8.8%) | 38 (11.3%) | 69 (25.4%) | 12(16.0%) | 23 (7.0%) |
*Ages 2-17 years |
Two cases of septic arthritis have been reported in infants less than one year of age in clinical trials conducted with Elidel Cream, 1% (n = 2,443). Causality has not been established.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Elidel Cream, 1%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General
Anaphylactic reactions, ocular irritation after application of the cream to the eye lids or near the eyes, angioneurotic edema, facial edema, skin flushing associated with alcohol use, skin discoloration.
Hematology/Oncology
Lymphomas, basal cell carcinoma, malignant melanoma, squamous cell carcinoma.
What drugs interact with Elidel (pimecrolimus)?
Potential interactions between Elidel Cream, 1% and other drugs, including immunizations, have not been systematically evaluated. Due to low blood levels of pimecrolimus detected in some patients after topical application, systemic drug interactions are not expected, but cannot be ruled out.
The concomitant administration of known CYP3A family of inhibitors in patients with widespread and/or erythrodermic disease should be done with caution.
Some examples of such drugs are
- erythromycin,
- itraconazole,
- ketoconazole,
- fluconazole,
- calcium channel blockers and
- cimetidine.
Summary
Elidel (pimecrolimus) is an immunosuppressant used to treat atopic dermatitis (eczema), a skin condition characterized by redness, itching, scaling, and inflammation of the skin. Common side effects of Elidel include application site reactions (burning, itching, and redness), sore throat, stuffy nose, headache, cough, respiratory tract and viral infections. Serious side effects of Elidel include skin cancer and lymphoma (rare). There are no adequate studies that evaluate the use of Elidel during pregnancy. Use of Elidel by nursing mothers has not been evaluated, and it is unknown if Elidel is excreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
-
Eczema (Atopic Dermatitis) Causes, Symptoms, Treatment
Eczema (Atopic Dermatitis) is a common allergic skin condition. Get the latest information on causes of eczema and skin rash...
-
Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Does dry, itchy, flaky, scaly, red, inflamed skin sound familiar to you? Take the Atopic Eczema (Atopic Dermatitis) Quiz to learn...
-
Picture of Nummular Eczema
Coin-shaped patches of irritated skin-most common on the arms, back, buttocks, and lower legs that may be crusted, scaling, and...
-
Picture of Eczema
A particular type of inflammatory reaction of the skin in which there are typically vesicles (tiny blister-like raised areas) in...
-
Picture of Atopic Dermatitis
This condition is the most common of all pediatric dermatoses. See a picture of Atopic Dermatitis and learn more about the...
-
Picture of Eczema Herpeticum
Eczema herpeticum. See a picture of Eczema Herpeticum and learn more about the health topic.
-
Picture of Atopic Dermatitis or Eczema
Eczema is a skin condition caused by inflammation. See a picture of Atopic Dermatitis or Eczema and learn more about the health...
Related Disease Conditions
-
Atopic Dermatitis
Eczema is a general term for many types dermatitis (skin inflammation). Atopic dermatitis is the most common of the many types of eczema. Other types of eczema include: contact eczema, allergic contact eczema, seborrheic eczema, nummular eczema, stasis dermatitis, and dyshidrotic eczema.
-
Eczema
Eczema refers to skin inflammation. There are many different types of eczema that produce symptoms and signs that range from oozing blisters to crusty plaques of skin. Treatment varies depending upon the type of eczema the person has.
-
Is Eczema Contagious?
Eczema is a skin condition characterized by inflamed, rough skin patches that occasionally produce fluid-filled bumps that may ooze. There is no cure for eczema, though eczema may be treated with moisturization, eczema cream, and topical steroids.
-
Ringworm vs. Eczema
While ringworm is a fungal infection, and eczema is a skin condition, both are characterized by itchiness. Eczema patches are leathery while ringworm involves ring formation on the skin. Over-the-counter antifungals treat ringworm. Topical creams and ointments treat eczema.
-
Atopic Dermatitis vs. Eczema
Atopic dermatitis and eczema both refer to skin conditions. Atopic dermatitis is a cause of eczema, which refers to skin conditions that cause inflammation and irritation. The terms are sometimes used interchangeably. Eczema is not a condition in itself, but a description for a group of skin diseases that cause skin inflammation and irritation.
Treatment & Diagnosis
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.